Quarterly report pursuant to Section 13 or 15(d)

License and Collaboration Agreement (Details)

v3.23.1
License and Collaboration Agreement (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Aug. 17, 2021
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2020
Sep. 15, 2022
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Revenues   $ 34,409 $ 21,625    
Research and development   13,158 12,620    
Otuska | License Agreement Terms          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Upfront payments received       $ 50,000  
Potential regulatory milestone revenue       $ 50,000  
Triggered milestone, payments         $ 30,000
Otuska | License Agreement Terms | Service Revenue          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Revenues   $ 100 100    
Otuska | License Agreement Terms | Minimum          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Tiered royalty percentages on future sales       10.00%  
Otuska | License Agreement Terms | Maximum          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Tiered royalty percentages on future sales       20.00%  
Riptide Bioscience, Inc. | License Agreement Terms          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Upfront license fee $ 6,000        
Research and development     $ 4,000